$ニューロセンス・セラピューティクス(NRSN.US)$Neurosense Therapeutics: Study Expected to Reveal Safety of Primec in Ad, and Shed Light on Efficacy, Biological Activity of Combination Therapy
$ニューロセンス・セラピューティクス(NRSN.US)$Neurosense and Genetika+ Initiate Precision Medicine Collaboration Beginning With Ongoing Phase 2 Clinical Trial in Alzheimer's Disease
5
報告
Jaguar8 :
Super super like. I have genes of Alzheimer’s
Trytosaveabitスレ主Jaguar8:
Exactly! That’s why I say much more with blue pill needs done! Preliminary research shows what you say and why Sildenafil could be the treatment
$ニューロセンス・セラピューティクス(NRSN.US)$ NEWS NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting Positive clinical outcomes from the PARADIGM Phase 2b study of PrimeC for ALS Statistically significant slowing of disease progression by 37% in the per-protocol population Validation of topline data by the American Academy of Neurology Positive trend towards impacting Neurofilament biomarker level...
$ニューロセンス・セラピューティクス(NRSN.US)$NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement PR Newswire· 8 mins ago CAMBRIDGE, Mass., April 10, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase agreement with a single health-care focused institutional investor fo...
NeuroSense Makes Significant Strides in ALS Treatment with Positive Phase 2b Trial Results. In a pivotal development for the treatment of Amyotrophic Lateral Sclerosis (ALS), NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has reported additional positive results from its Phase 2b PARADIGM trial. The company's lead drug candidate, PrimeC, demonstrated substantial clinical efficacy, marking a significant milest...
$ニューロセンス・セラピューティクス(NRSN.US)$NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial 6 MINUTES AGO, 8:30 AM EST VIA PR NEWSWIRE • PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALS • Standard ALS Measure ALSFRS-R already demonstrated a statistically significant effect of PrimeC on slowing down disease progression • Further analysis of PARADIGM is on track with neurofilament resu...
$ニューロセンス・セラピューティクス(NRSN.US)$NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024 ACCESSWIRE 30-Jan-2024 8:32 AM
$ニューロセンス・セラピューティクス(NRSN.US)$my apologies 44 dollars still doesn’t make sense. why don’t they let them buy them at that price of they want them. would teach them to stop bidding bullshit
ニューロセンス・セラピューティクスに関するコメント
A bit more
Update
NEWS
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
Positive clinical outcomes from the PARADIGM Phase 2b study of PrimeC for ALS
Statistically significant slowing of disease progression by 37% in the per-protocol population
Validation of topline data by the American Academy of Neurology
Positive trend towards impacting Neurofilament biomarker level...
Update
PR Newswire· 8 mins ago
CAMBRIDGE, Mass., April 10, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase agreement with a single health-care focused institutional investor fo...
NeuroSense Makes Significant Strides in ALS Treatment with Positive Phase 2b Trial Results.
In a pivotal development for the treatment of Amyotrophic Lateral Sclerosis (ALS), NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) has reported additional positive results from its Phase 2b PARADIGM trial. The company's lead drug candidate, PrimeC, demonstrated substantial clinical efficacy, marking a significant milest...
Update
6 MINUTES AGO, 8:30 AM EST
VIA PR NEWSWIRE
• PrimeC demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients with ALS
• Standard ALS Measure ALSFRS-R already demonstrated a statistically significant effect of PrimeC on slowing down disease progression
• Further analysis of PARADIGM is on track with neurofilament resu...
Update
ACCESSWIRE 30-Jan-2024 8:32 AM
まだコメントはありません